deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT04797650

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Sponsor: Concert Pharmaceuticals

Updated 15 times since 2021 Last updated: Jun 30, 2023 Started: Jun 10, 2021 Primary completion: Jun 8, 2022 Completion: Jun 29, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04797650, this PHASE3 trial focuses on Alopecia Areata and remains completed. Sponsored by Concert Pharmaceuticals, it has been updated 15 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Aug 2023 · 10 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2022 — Aug 2023 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

Show 10 earlier versions
  1. Sep 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  3. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  7. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  8. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  9. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  10. Apr 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Concert Pharmaceuticals
Data source: Concert Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .